$SSII
SS Innovations International, Inc. Stock $ssii

$ssii Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000121390023025143 Filed on March 31, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue		$0.00
YoY Change
Cost Of Revenue	$1.000M	$315.7K	$1.135M
YoY Change	3441.78%	134.12%	19.87%
Gross Profit	$511.2K	-$315.7K	-$1.135M
YoY Change	-1910.13%	134.12%	19.87%
Gross Profit Margin
Selling, General & Admin	$1.417M	$908.3K	$1.239M
YoY Change	2613.44%	541.8%	170.09%
% of Gross Profit	277.19%
Research & Development		$72.96K	$72.96K
YoY Change			7195.9%
% of Gross Profit
Depreciation & Amortization	$2.280K	$2.280K	$9.140K
YoY Change	-1.3%	-23.49%	-51.36%
% of Gross Profit	0.45%
Operating Expenses	$2.057M	$981.2K	$2.448M
YoY Change	2456.76%	593.41%	73.95%
Operating Profit	-$1.546M	-$1.297M	-$3.583M
YoY Change	1322.21%	369.29%	52.19%
Interest Expense	$67.70K	-$45.49K	$45.53K
YoY Change		-151733.33%	37840.83%
% of Operating Profit
Other Income/Expense, Net	$52.75K	$170.0K	$234.6K
YoY Change	150605.71%	-319.64%	-403.59%
Pretax Income	-$2.004M	-$1.172M	-$2.213M
YoY Change	2392.28%	231.46%	49.09%
Income Tax		$0.00
% Of Pretax Income
Net Earnings	-$2.004M	-$1.172M	-$2.213M
YoY Change	2392.28%	231.46%	49.09%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.03		-$0.05
Diluted Earnings Per Share	-$0.03	-$0.02	-$0.05
COMMON SHARES
Basic Shares Outstanding	53.89M shares	39.20M shares	40.88M shares
Diluted Shares Outstanding	61.71M shares		40.88M shares

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$448.5K	$1.351M	$1.351M
YoY Change	29.31%	233.04%	233.04%
Cash & Equivalents	$448.5K	$1.351M	$1.351M
Short-Term Investments
Other Short-Term Assets	$8.680K	$8.680K	$8.680K
YoY Change	279.04%	279.04%	279.04%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$5.457M	$4.360M	$4.360M
YoY Change	1462.96%	968.47%	968.45%
LONG-TERM ASSETS
Property, Plant & Equipment	$9.120K	$11.40K	$11.40K
YoY Change	-49.99%	-44.51%	-44.5%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$9.120K	$11.40K	$11.40K
YoY Change	-49.99%	-44.51%	-44.5%
TOTAL ASSETS
Total Short-Term Assets	$5.457M	$4.360M	$4.360M
Total Long-Term Assets	$9.120K	$11.40K	$11.40K
Total Assets	$5.466M	$4.371M	$4.371M
YoY Change	1387.86%	919.92%	919.91%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable			$0.00
YoY Change			-100.0%
Accrued Expenses	$5.700K	$5.700K	$51.23K
YoY Change	-70.31%	-67.8%	189.44%
Deferred Revenue
YoY Change
Short-Term Debt	$5.000M	$4.000M	$4.000M
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$5.119M	$4.051M	$4.051M
YoY Change	1739.69%	1310.2%	1310.2%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities		$0.00	$0.00
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$5.119M	$4.051M	$4.051M
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$5.119M	$4.051M	$4.051M
YoY Change	1739.69%	1310.2%	1310.2%
SHAREHOLDERS EQUITY
Retained Earnings	-$12.70M	-$10.69M
YoY Change	48.34%	26.1%
Common Stock	$6.544K	$5.389K
YoY Change	72.89%	42.38%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$347.4K	$320.2K	$320.2K
YoY Change
Total Liabilities & Shareholders Equity	$5.466M	$4.371M	$4.371M
YoY Change	1387.86%	919.92%	919.91%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$2.004M	-$1.172M	-$2.213M
YoY Change	2392.28%	231.46%	49.09%
Depreciation, Depletion And Amortization	$2.280K	$2.280K	$9.140K
YoY Change	-1.3%	-23.49%	-51.36%
Cash From Operating Activities	-$336.6K	-$1.132M	-$1.436M
YoY Change	471.51%	887.72%	295.51%
INVESTING ACTIVITIES
Capital Expenditures			$220.3K
YoY Change
Acquisitions
YoY Change
Other Investing Activities	-$2.000M	-$1.900M	-$3.000M
YoY Change		-7407.69%	-7963.7%
Cash From Investing Activities	-$2.000M	-$1.900M	-$3.000M
YoY Change		-7407.69%	-7963.7%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$1.434M	3.869M	$5.381M
YoY Change		1237.95%	844.2%
NET CHANGE
Cash From Operating Activities	-$336.6K	-1.132M	-$1.436M
Cash From Investing Activities	-$2.000M	-1.900M	-$3.000M
Cash From Financing Activities	$1.434M	3.869M	$5.381M
Net Change In Cash	-$902.8K	837.2K	-$945.6K
YoY Change	1432.67%	317.4%	-485.85%
FREE CASH FLOW
Cash From Operating Activities	-$336.6K	-$1.132M	-$1.436M
Capital Expenditures			$220.3K
Free Cash Flow	-$336.6K		-$1.656M
YoY Change	471.51%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2021Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent		usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Entity File Number EntityFileNumber	333-216054
CY2022	dei	Entity Registrant Name EntityRegistrantName	AVRA MEDICAL ROBOTICS, INC
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	FL
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	47-3478854
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	3259 Progress Drive
CY2022	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 114
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Orlando
CY2022	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	32826
CY2022	dei	City Area Code CityAreaCode	(407)
CY2022	dei	Local Phone Number LocalPhoneNumber	956-2250
CY2022	dei	Security12b Title Security12bTitle	None
CY2022	dei	Trading Symbol TradingSymbol	N/A
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	No
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2022	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	53887738	shares
CY2022	dei	Auditor Name AuditorName	BF Borgers CPA PC
CY2022	dei	Auditor Firm AuditorFirmId	5041
CY2022	dei	Auditor Location AuditorLocation	Lakewood, CO
CY2022Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	1351364	usd
CY2021Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	405774	usd
CY2022Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	8678	usd
CY2021Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	2291	usd
CY2022Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	3000000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	4360042	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	408065	usd
CY2022Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	98592	usd
CY2021Q4	us-gaap	Machinery And Equipment Gross MachineryAndEquipmentGross	98592	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	87193	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	78050	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	11399	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	20542	usd
CY2022Q4	us-gaap	Assets Assets	4371441	usd
CY2021Q4	us-gaap	Assets Assets	428607	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	124581	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5700	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	17700	usd
CY2022Q4	us-gaap	Interest Payable Current InterestPayableCurrent	45529	usd
CY2022Q4	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	4000000	usd
CY2021Q4	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	145000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	4051229	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	287281	usd
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	53887738	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	53887738	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	37848905	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	37848905	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	5389	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	3785	usd
CY2022Q4	us-gaap	Excess Stock Shares Issued ExcessStockSharesIssued	0	shares
CY2021Q4	us-gaap	Excess Stock Shares Issued ExcessStockSharesIssued	4265295	shares
CY2022Q4	avmr	Common Stock Liabilities Par Value CommonStockLiabilitiesParValue	0.0001
CY2021Q4	avmr	Common Stock Liabilities Par Value CommonStockLiabilitiesParValue	0.0001
CY2021Q4	avmr	Commonstockvalue1 Commonstockvalue1	458519	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	11005895	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	8183082	usd
CY2021Q4	us-gaap	Treasury Stock Value TreasuryStockValue	26000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-10691071	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-8478060	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	320213	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	141326	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	4371441	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	428607	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	72959	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1000	usd
CY2022	avmr	Compensation Expense CompensationExpense	1135468	usd
CY2021	avmr	Compensation Expense CompensationExpense	947237	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1239179	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	458801	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	2447606	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	1407038	usd
CY2021	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-77392	usd
CY2022	us-gaap	Investment Income Net InvestmentIncomeNet	148	usd
CY2021	us-gaap	Investment Income Net InvestmentIncomeNet	118	usd
CY2022	us-gaap	Interest Expense InterestExpense	45529	usd
CY2022	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	279975	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	234594	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-77274	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2213012	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1484313	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-2213012	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-1484313	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.05
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.05
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	40878824	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	28480973	shares
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-2213012	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-1484313	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	9143	usd
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	18787	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	865468	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	767237	usd
CY2021	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	1107500	usd
CY2021	us-gaap	Gain Loss On Investments GainLossOnInvestments	-77392	usd
CY2022	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	6387	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-91052	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-849637	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1435841	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-363034	usd
CY2022	us-gaap	Payments To Acquire Notes Receivable PaymentsToAcquireNotesReceivable	3000000	usd
CY2021	us-gaap	Proceeds From Sale Of Other Investments ProceedsFromSaleOfOtherInvestments	38150	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-3000000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	38150	usd
CY2022	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	145000	usd
CY2022	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	4000000	usd
CY2021	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	315200	usd
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	12900	usd
CY2022	avmr	Proceeds From Securities Offering ProceedsFromSecuritiesOffering	1500431	usd
CY2021	avmr	Proceeds From Securities Offering ProceedsFromSecuritiesOffering	267850	usd
CY2022	avmr	Treasury Stock TreasuryStock	26000	usd
CY2021	avmr	Treasury Stock TreasuryStock	-26000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	5381431	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	569949	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-945590	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	245065	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	405774	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	160709	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1351364	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	405774	usd
CY2021	avmr	Cash Received For Interest CashReceivedForInterest	118	usd
CY2021	avmr	Related Party Note Payable Converted To Common Stock RelatedPartyNotePayableConvertedToCommonStock	50000	usd
CY2021	avmr	Reduction Of Account Payable And Equipment ReductionOfAccountPayableAndEquipment	9543	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-869049	usd
CY2021	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation	862849	usd
CY2021	avmr	Common Stock Issuable For Services CommonStockIssuableForServices	869668	usd
CY2021	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	50000	usd
CY2021	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits	146273	usd
CY2021	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	276697	usd
CY2021	us-gaap	Payments For Repurchase Of Private Placement PaymentsForRepurchaseOfPrivatePlacement	315200	usd
CY2021	avmr	Treasury Stock TreasuryStock	-26000	usd
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	0	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-1484313	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	141326	usd
CY2022	us-gaap	Stock Granted During Period Value Sharebased Compensation StockGrantedDuringPeriodValueSharebasedCompensation	679611	usd
CY2022	avmr	Common Stock Issuable For Services CommonStockIssuableForServices	-53518	usd
CY2022	avmr	Treasury Stock TreasuryStock	26000	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1739806	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-2213012	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	320213	usd
CY2022	us-gaap	Stockholders Equity Other StockholdersEquityOther	320231	usd
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Estimates</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and expenses. The Company regularly evaluates estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates made by management.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">Concentration of Credit Risk</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash. The Company maintains its principal cash balance in a financial institution. These balances are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to $250,000. At December 31, 2022 and 2021, $0 and $147,460, respectively, were in excess of the FDIC insured limit.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2022Q4	avmr	Fdic Insured FDICInsured	250000	usd
CY2022Q4	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	0	usd
CY2021Q4	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	147460	usd
CY2022	us-gaap	Property Plant And Equipment Useful Life PropertyPlantAndEquipmentUsefulLife	P5Y
CY2022	us-gaap	Property Plant And Equipment Cost Capitalization PropertyPlantAndEquipmentCostCapitalization	$75,000
CY2022	us-gaap	Public Utilities Property Plant And Equipment Disclosure Of Composite Depreciation Rate For Plants In Service PublicUtilitiesPropertyPlantAndEquipmentDisclosureOfCompositeDepreciationRateForPlantsInService	1	pure
CY2020Q1	avmr	Vendor Due To Issues Equipment Amount VendorDueToIssuesEquipmentAmount	25000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Other PropertyPlantAndEquipmentOther	50000	usd
	us-gaap	Proceeds From Sale Of Other Investments ProceedsFromSaleOfOtherInvestments	12150	usd
CY2021	us-gaap	Other Asset Impairment Charges OtherAssetImpairmentCharges	77392	usd
CY2022Q4	avmr	Original Investment Cost OriginalInvestmentCost	26000	usd
CY2022Q4	us-gaap	Investment Owned At Cost InvestmentOwnedAtCost	0	usd
CY2021Q3	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	50000	usd
CY2021Q3	us-gaap	Conversion Of Stock Shares Converted1 ConversionOfStockSharesConverted1	384615	shares
CY2021	avmr	Warrants Warrants	1175000	shares
CY2022	avmr	Warrants Warrants	0	shares
CY2021Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.78
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	912489	usd
CY2022	us-gaap	Employee Stock Ownership Plan Esop Compensation Expense EmployeeStockOwnershipPlanESOPCompensationExpense	0	usd
CY2022	avmr	Accured Interest Percentage AccuredInterestPercentage	0.07	pure
CY2022Q4	avmr	Original Issue Discount Amount OriginalIssueDiscountAmount	2000000	usd
CY2022Q4	us-gaap	Deposit Liabilities Accrued Interest DepositLiabilitiesAccruedInterest	100000000	usd
CY2022Q4	us-gaap	Investment Owned Balance Principal Amount InvestmentOwnedBalancePrincipalAmount	2000000	usd
CY2022Q4	avmr	Original Issue Discount Rate OriginalIssueDiscountRate	0.06	pure
CY2022Q4	avmr	Original Issue Discount Opposed Rate OriginalIssueDiscountOpposedRate	0.10	pure
CY2022	avmr	Valuation For Determining Conversion ValuationForDeterminingConversion	250000000	usd
CY2022	avmr	Valuation For Determining Conversion Opposed Value ValuationForDeterminingConversionOpposedValue	100000000	usd
CY2022	avmr	Promissory Notes Description PromissoryNotesDescription	In order to fund the Interim Financing, the Company offered and sold one-year convertible promissory notes (the “Convertible Notes”) of $1,000,000 (maturity date 08-15-2023), $500,000 (maturity date 10-26-2023), and $500,000 (maturity date 12-01-2023) to one accredited investor and $100,000 (maturity date 09-10-2023), $900,000 (maturity date 11-23-2023), and $1,000,000 (maturity date 12-29-2023) to another. The Convertible Notes will have the same interest rate and payment terms as the Cardio Notes and otherwise be substantially similar to the Cardio Notes, provided, however, that the Convertible Notes do not have an original issue discount. Further, upon consummation of the Transaction (if and when it is consummated) the Convertible Notes will automatically convert into a number of AVRA Shares determined by dividing the principal amount of the Convertible Notes by $100 million and multiplying such number expressed as a percentage by the number of AVRA Shares issued to Dr. Sudhir and the other shareholders of the SSI Parties (if any) upon closing of the Transaction. The Company may offer and sell up to an aggregate principal amount of $5,000,000 in Convertible Notes in order to fund the Interim Financing.
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards Subject To Expiration DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration	4393785	usd
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2020	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	0	usd
CY2020	us-gaap	Gain Loss On Sale Of Leased Assets Net Operating Leases GainLossOnSaleOfLeasedAssetsNetOperatingLeases	221827	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	usd
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	usd
	avmr	Shares Issued For Services Rendered SharesIssuedForServicesRendered	378378	shares
CY2021Q3	us-gaap	Excess Stock Shares Issued ExcessStockSharesIssued	629375	shares
CY2021	avmr	Shares Issued For Services Rendered SharesIssuedForServicesRendered	3619817	shares
CY2022	avmr	Number Of Common Stock Sold NumberOfCommonStockSold	10000	shares
CY2022	us-gaap	Dividends Share Based Compensation DividendsShareBasedCompensation	679612	usd
CY2021	us-gaap	Dividends Share Based Compensation DividendsShareBasedCompensation	159949	usd
CY2021Q4	us-gaap	Excess Stock Shares Issued ExcessStockSharesIssued	1500000	shares
CY2021Q4	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1	0.25
CY2022Q2	us-gaap	Excess Stock Shares Issued ExcessStockSharesIssued	150000	shares
CY2022Q2	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1	0.1
CY2022Q3	us-gaap	Excess Stock Shares Issued ExcessStockSharesIssued	3020000	shares
CY2022Q3	us-gaap	Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1 SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1	0.1
CY2020Q3	us-gaap	Operating Lease Expense OperatingLeaseExpense	1474.17	usd
CY2021Q1	us-gaap	Operating Lease Expense OperatingLeaseExpense	1964.74	usd
CY2022Q4	us-gaap	Repurchase Agreements Interest Expense Amount RepurchaseAgreementsInterestExpenseAmount	404.68	usd
CY2022	avmr	Interim Financing Notes Value InterimFinancingNotesValue	4000000	usd
CY2023Q1	us-gaap	Proceeds From Other Equity ProceedsFromOtherEquity	189500	usd
CY2021Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent		usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent		usd
CY2022Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent		usd
CY2021Q4	us-gaap	Interest Payable Current InterestPayableCurrent		usd
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent		usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued		shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding		shares
CY2022Q4	avmr	Commonstockvalue1 Commonstockvalue1		usd
CY2022Q4	us-gaap	Treasury Stock Value TreasuryStockValue		usd
CY2022	us-gaap	Revenues Revenues		usd
CY2021	us-gaap	Revenues Revenues		usd
CY2022	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments		usd
CY2021	us-gaap	Interest Expense InterestExpense		usd
CY2021	us-gaap	Other Nonoperating Income OtherNonoperatingIncome		usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.05
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	28480973	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	40878824	shares
CY2022	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims		usd
CY2022	us-gaap	Gain Loss On Investments GainLossOnInvestments		usd
CY2021	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense		usd
CY2021	us-gaap	Payments To Acquire Notes Receivable PaymentsToAcquireNotesReceivable		usd
CY2022	us-gaap	Proceeds From Sale Of Other Investments ProceedsFromSaleOfOtherInvestments		usd
CY2021	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt		usd
CY2021	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt		usd
CY2022	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement		usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised		usd
CY2022	avmr	Cash Received For Interest CashReceivedForInterest		usd
CY2022	avmr	Related Party Note Payable Converted To Common Stock RelatedPartyNotePayableConvertedToCommonStock		usd
CY2022	avmr	Reduction Of Account Payable And Equipment ReductionOfAccountPayableAndEquipment		usd
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001676163
CY2022Q2	dei	Entity Public Float EntityPublicFloat	0	usd

Files In Submission

Name	View Source	Status
0001213900-23-025143-index-headers.html	Edgar Link	pending
0001213900-23-025143-index.html	Edgar Link	pending
0001213900-23-025143.txt	Edgar Link	pending
0001213900-23-025143-xbrl.zip	Edgar Link	pending
avmr-20221231.xsd	Edgar Link	pending
avmr-20221231_lab.xml	Edgar Link	unprocessable
avmr-20221231_def.xml	Edgar Link	unprocessable
avmr-20221231_cal.xml	Edgar Link	unprocessable
f10k2022ex31-1_avramedical.htm	Edgar Link	pending
f10k2022ex32-1_avramedical.htm	Edgar Link	pending
f10k2022_avramedical.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
avmr-20221231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
f10k2022_avramedical_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SSII
SS Innovations International, Inc. Stock $ssii

2023 Q1 Form 10-K Financial Statement

#000121390023025143 Filed on March 31, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SSII SS Innovations International, Inc. Stock $ssii

2023 Q1 Form 10-K Financial Statement

#000121390023025143 Filed on March 31, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SSII
SS Innovations International, Inc. Stock $ssii